Journal of Biomedical Science 2015, 22:71.
This report demonstrates therapeutic efficacy of NEO212 in preclinical models of nasopharyngeal carcinoma (NPC). Due to its hidden location behind the nose, this cancer type is difficult to access by surgery and generally is hard to treat. The finding that NEO212 exerts therapeutic activity against NPC in mouse models, points to the possibility that NPC patients might benefit from this drug. In this case, intranasal (through the nose) delivery would be expected to be especially effective, because it would place the treatment in close proximity to the primary tumor.